المؤلفون: Dardano, Angela, Aragona, Michele, Daniele, Giuseppe, Miccoli, Roberto, Del Prato, Stefano

المصدر: Frontiers in Endocrinology ; volume 13 ; ISSN 1664-2392

الوصف: Background Type 2 diabetes (T2D) is a common comorbidity in people living with HIV (PLWH). Anti-hyperglycemic treatment in PLWH is still a challenge, and no randomized controlled studies using new glucose-lowering agents are currently available. Case Description A 55-year-old-women was admitted to our Diabetes Unit because of hyperosmolar hyperglycemic state (HHS) and sepsis. The medical history included HIV infection and insulin-treated diabetes. On clinical examination, the lady appeared dehydrated with dry buccal mucosa, tachycardia, altered mental status, genital infection, and fever. On admission, plasma glucose was 54.5 mmol/L, HbA1c 155 mmol/mol, osmolarity 389.4 mOsm/kg, bicarbonate 24.6 mmol/L with no detectable serum ketones. The patient was treated with i.v. fluid and insulin, and antibiotic therapy commenced. Upon HHS and sepsis resolution, a basal-bolus insulin therapy was implemented that was followed by significant improvement of daily glucose profiles and progressive reduction of insulin requirement until complete discontinuation. A low dose of metformin plus linagliptin was started. Since a severe atherosclerotic disease was diagnosed, a GLP-1 receptor agonist, dulaglutide, was added to metformin upon linagliptin withdrawal with maintenance of good glycemic control, treatment adherence and amelioration of quality of life and no side effects. Conclusion This case suggests that GLP-1 receptor agonist therapy may be effective and safe for treatment of T2D with high cardiovascular risk in PLWH, supporting the need of clinical trials directly assessing the safety and the efficacy of GLP-1 receptor agonist in these individuals.

الإتاحة: https://doi.org/10.3389/fendo.2022.847778Test

المؤلفون: Dardano, Angela, Daniele, Giuseppe, Penno, Giuseppe, Miccoli, Roberto, Del Prato, Stefano

المصدر: Frontiers in Medicine ; volume 8 ; ISSN 2296-858X

مصطلحات موضوعية: General Medicine

الوصف: Background: Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner as per evidence-based clinical guidelines, is an important barrier limiting optimal care in the elderly. Therefore, overcoming therapeutic inertia is the core challenge when dealing with geriatric patients. Case Description: The patient was an 80-year-old man that attended our Outpatient Lipid Clinic (Pisa University Hospital) because of persistent high LDL cholesterol (LDLc) levels in a setting of a statin contraindication. He underwent five percutaneous coronary angioplasties with drug-eluting stents. In 2014, upon starting treatment with rosuvastatin for LDLc level of 7.59 mmol/L, the patient was admitted to the Emergency Room for a presumptive diagnosis of rhabdomyolysis (creatine kinase 6685 U/L) secondary to statin. Patient developed acute kidney injury treated with dialysis. After resolution, he was discharged with ezetimibe (10 mg daily). This treatment however failed to effectively reduce LDLc levels that ranged between 5.9 and 6.6 mmol/L for the ensuing 4-years. In 2018, at the time of our evaluation, in consideration of the age, we performed a comprehensive geriatric assessment that showed good functional and mental status supporting a reliable treatment with a proprotein convertase subtilisin–kexin type 9 inhibitor. Therefore, alirocumab was prescribed as add-on to ezetimibe. At 24-month follow-up, the geriatric assessment showed no significant changes, and alirocumab was well-tolerated. LDLc was 82% lower as compared to baseline values (from 6.6 to 1.2 mmol/L). Conclusions: This report describes a case of therapeutic inertia despite a very high-risk profile. It is also instrumental in highlightening that appropriate intensification of therapy in an elderly patient at high cardiovascular risk, by means of a patient-centered approach, may allow reaching therapeutic targets and overcoming the condition of therapeutic inertia.

الإتاحة: https://doi.org/10.3389/fmed.2021.699477Test

المؤلفون: Garofolo, Monia, Gualdani, Elisa, Giannarelli, Rosa, Aragona, Michele, Campi, Fabrizio, Lucchesi, Daniela, Daniele, Giuseppe, Miccoli, Roberto, Francesconi, Paolo, Del Prato, Stefano, Penno, Giuseppe

المساهمون: Garofolo, Monia, Gualdani, Elisa, Giannarelli, Rosa, Aragona, Michele, Campi, Fabrizio, Lucchesi, Daniela, Daniele, Giuseppe, Miccoli, Roberto, Francesconi, Paolo, Del Prato, Stefano, Penno, Giuseppe

مصطلحات موضوعية: All-cause mortality, Cardiovascular disease, Diabetic kidney disease, Diabetic retinopathy, Microvascular burden, Microvascular complication, Peripheral diabetic polyneuropathy, Type 1 diabetes mellitus

الوصف: Background: Microvascular complications (MC) have been claimed to increase the risk for cardiovascular disease in diabetic subjects. However, the effect of MC burden on the risk of major vascular outcomes and all-cause mortality in type 1 diabetes is still poorly explored. We evaluated the relationship between microvascular complications burden and incidence of major cardiovascular events and all-cause mortality in subjects with type 1 diabetes. Methods: We recruited 774 participants with type 1 diabetes in a single-center observational study over a follow-up of 10.8 ± 2.5 years. Hazard ratios (HR) for cardiovascular outcomes and all-cause death associated with microvascular complications were determined by unadjusted and adjusted Cox regression analysis. Results: Out of 774 individuals, 54.9% had no-MC, 32.3% 1 MC, 9.7% 2 MC and 3.1% 3 MC. A total of 54 deaths (7.0%) occurred. Death rate increased from no-MC 2.1% (Ref) to 1 MC 7.2% (HR 3.54 [95% CI 1.59-7.87]), 2 MC 14.7% (HR 6.41 [95% CI 2.65-15.49]) and 3 MC 66.7% (HR 41.73 [95% CI 18.42-94.57], p < 0.0001). After adjustments, HRs were: 1 MC 2.05 (95% CI 0.88-4.76), 2 MC 1.98 (95% CI 0.75-5.21), 3 MC 7.02 (95% CI 2.44-20.20, p = 0.002). Forty-nine subjects (6.7%) had at least one cardiovascular event, and cumulative incidence went from no-MC 2.2% (Ref) to 1 MC 5.0%; (HR 2.27 [95% CI 0.96-5.38]), 2 MC 26.8% (HR 12.88 [95% CI 5.82-28.50]) and 3 MC 40.9% (HR 29.34 [95% CI 11.59-74.25], p < 0.0001). Upon adjustments, HRs were: 1 MC 1.59 (95% CI 0.65-3.88), 2 MC 4.33 (95% CI 1.75-10.74), 3 MC 9.31 (95% CI 3.18-27.25, p < 0.0001). Thirty-five individuals (4.8%) had at least one coronary event, which cumulative incidence increased with MC burden (p < 0.0001). Conclusions: In type 1 diabetes, microvascular complications burden increases in an independent dose-dependent manner the risk of major cardiovascular outcomes and all-cause mortality. The presence and number of microvascular complications should be considered in stratifying overall cardiovascular ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31733651; info:eu-repo/semantics/altIdentifier/wos/WOS:000497734800004; volume:18; issue:1; journal:CARDIOVASCULAR DIABETOLOGY; http://hdl.handle.net/11568/1017892Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85075114771; http://www.cardiab.com/homeTest/

الإتاحة: https://doi.org/10.1186/s12933-019-0961-7Test
http://hdl.handle.net/11568/1017892Test
http://www.cardiab.com/homeTest/

المؤلفون: Bonora, Enzo, Cataudella, Salvatore, Marchesini, Giulio, Miccoli, Roberto, Vaccaro, Olga, Fadini, Gian Paolo, Martini, Nello, Rossi, Elisa

المساهمون: Italian Diabetes Society

المصدر: BMJ Open Diabetes Research & Care ; volume 8, issue 1, page e001191 ; ISSN 2052-4897

الوصف: Introduction Diabetes is a highly prevalent disease worldwide and represents a challenge for patients and healthcare systems. This population-based study evaluated diabetes burden in Italy in 2018 by assessing all aspects of outpatient and hospital care. Research design and methods We investigated data of 11 300 750 residents in local health districts contributing to ARNO Diabetes Observatory (~20% of Italian inhabitants). All administrative healthcare claims were analyzed to gather information on access to medical resources. Subjects with diabetes, identified by antihyperglycemic drug prescriptions, disease-specific copayment exemption and hospital discharge codes, were compared with age, sex and residency-matched non-diabetic individuals. Results We identified 697 208 subjects with ascertained diabetes, yielding a prevalence of 6.2% (6.5% in men vs 5.9% in women, p<0.001). Age was 69±15 (mean±SD). As compared with non-diabetic subjects, patients with diabetes received more prescriptions of any drugs (+30%, p<0.001), laboratory tests, radiologic exams and outpatient specialist consultations (+20%, p<0.001) and were hospitalized more frequently (+86%, p<0.001), with a longer stay (+1.4 days, p<0.001). Although cardiovascular diseases accounted for many hospital discharge diagnoses, virtually all diseases contributed to the higher rate of hospital admissions in diabetic subjects (235 vs 99 per 1000 person-years, p<0.001). Healthcare costs were >2-fold higher in subjects with diabetes, mainly driven by hospitalizations and outpatient care related to chronic complications rather than to glucose-lowering drugs, diabetes-specific devices, or metabolic monitoring. Conclusions The burden of diabetes in Italy is particularly heavy and, as a systemic disease, it includes all aspects of clinical medicine, with consequent high expenses in all areas of healthcare.

الإتاحة: https://doi.org/10.1136/bmjdrc-2020-001191Test

المؤلفون: Dardano, Angela, Daniele, Giuseppe, Lupi, Roberto, Napoli, Niccolò, Campani, Daniela, Boggi, Ugo, Del Prato, Stefano, Miccoli, Roberto

المصدر: Frontiers in Endocrinology ; volume 11 ; ISSN 1664-2392

مصطلحات موضوعية: Endocrinology, Diabetes and Metabolism

الإتاحة: https://doi.org/10.3389/fendo.2020.00010Test

المؤلفون: Dardano, Angela, Miccoli, Roberto, Bianchi, Cristina, Daniele, Giuseppe, Del Prato, Stefano

المصدر: Diabetes Research and Clinical Practice ; volume 162, page 108112 ; ISSN 0168-8227

مصطلحات موضوعية: Endocrinology, General Medicine, Endocrinology, Diabetes and Metabolism, Internal Medicine

الإتاحة: https://doi.org/10.1016/j.diabres.2020.108112Test
https://api.elsevier.com/content/article/PII:S0168822720303624?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0168822720303624?httpAccept=text/plainTest

المؤلفون: Casula, Manuela, Olmastroni, Elena, Pirillo, Angela, Catapano, Alberico Luigi, Arca, Marcello, Averna, Maurizio, Bertolini, Stefano, Calandra, Sebastiano, Tarugi, Patrizia, Pellegatta, Fabio, Angelico, Francesco, Bartuli, Andrea, Biasucci, Giacomo, Biolo, Gianni, Bonanni, Luca, Bonomo, Katia, Borghi, Claudio, Bossi, Antonio Carlo, Branchi, Adriana, Carubbi, Francesca, Cipollone, Francesco, Citroni, Nadia, Federici, Massimo, Ferri, Claudio, Fiorenza, Anna Maria, Giaccari, Andrea, Giorgino, Francesco, Guardamagna, Ornella, Iannuzzi, Arcangelo, Iughetti, Lorenzo, Lupattelli, Graziana, Lupi, Alessandro, Mandraffino, Giuseppe, Marcucci, Rossella, Maroni, Lorenzo, Miccoli, Roberto, Mombelli, Giuliana, Muntoni, Sandro, Pecchioli, Valerio, Pederiva, Cristina, Pipolo, Antonio, Pisciotta, Livia, Pujia, Arturo, Purrello, Francesco, Repetti, Elena, Rubba, Paolo, Sabbà, Carlo, Sampietro, Tiziana, Sarzani, Riccardo, Tagliabue, Milena Paola, Trenti, Chiara, Vigna, Giovanni Battista, Werba, Josè Pablo, Zambon, Sabina, Zenti, Maria Grazia, Minicocci, Ilenia, Noto, Davide, Fortunato, Giuliana, Banderali, Giuseppe, Benso, Andrea, Bigolin, Paola, Bonora, Enzo, Bruzzi, Patrizia, Bucci, Marco, Buonuomo, Paola Sabrina, Capra, Maria Elena, Cardolini, Iris, Cefalù, Baldassarre, Cervelli, Nazzareno, Chiariello, Giuseppe, Cocci, Guido, Colombo, Emanuela, CREMONINI, ANNA LAURA, D'addato, Sergio, D'erasmo, Laura, Dal Pino, Beatrice, De Sanctis, Luisa, De Vita, Emanuele, Del Ben, Maria, Di Costanzo, Alessia, Di Taranto, Maria Donata, Fasano, Tommaso, Gentile, Luigi, Gentile, Marco, Ghirardello, Omar, Grigore, Liliana, Lussu, Milena, Meregalli, Giancarla, Moffa, Simona, Montalcini, Tiziana, Morgia, Valeria, Nascimbeni, Fabio, Pasta, Andrea, Pavanello, Chiara, Saitta, Antonino, Scicali, Roberto, Siepi, Donatella, Spagnolli, Walter, Spina, Rossella, Sticchi, Elena, Suppressa, Patrizia, Vigo, Lorenzo, Vinci, Pierandrea, Manzato, Enzo, Tragni, Elena, Zampoleri, Veronica

المساهمون: Casula, Manuela, Olmastroni, Elena, Pirillo, Angela, Catapano, Alberico Luigi, Arca, Marcello, Averna, Maurizio, Bertolini, Stefano, Calandra, Sebastiano, Tarugi, Patrizia, Pellegatta, Fabio, Angelico, Francesco, Bartuli, Andrea, Biasucci, Giacomo, Biolo, Gianni, Bonanni, Luca, Bonomo, Katia, Borghi, Claudio, Bossi, Antonio Carlo, Branchi, Adriana, Carubbi, Francesca, Cipollone, Francesco, Citroni, Nadia, Federici, Massimo, Ferri, Claudio, Fiorenza, Anna Maria, Giaccari, Andrea, Giorgino, Francesco, Guardamagna, Ornella, Iannuzzi, Arcangelo, Iughetti, Lorenzo, Lupattelli, Graziana, Lupi, Alessandro, Mandraffino, Giuseppe, Marcucci, Rossella, Maroni, Lorenzo, Miccoli, Roberto, Mombelli, Giuliana, Muntoni, Sandro, Pecchioli, Valerio, Pederiva, Cristina, Pipolo, Antonio, Pisciotta, Livia, Pujia, Arturo, Purrello, Francesco, Repetti, Elena, Rubba, Paolo, Sabbà, Carlo, Sampietro, Tiziana, Sarzani, Riccardo, Tagliabue, Milena Paola, Trenti, Chiara, Vigna, Giovanni Battista, Werba, Josè Pablo, Zambon, Sabina, Zenti, Maria Grazia, Minicocci, Ilenia, Noto, Davide, Fortunato, Giuliana, Banderali, Giuseppe, Benso, Andrea, Bigolin, Paola, Bonora, Enzo, Bruzzi, Patrizia, Bucci, Marco, Buonuomo, Paola Sabrina, Capra, Maria Elena, Cardolini, Iri, Cefalù, Baldassarre, Cervelli, Nazzareno, Chiariello, Giuseppe, Cocci, Guido, Colombo, Emanuela, Cremonini, Anna Laura, D'addato, Sergio, D'erasmo, Laura, Dal Pino, Beatrice, De Sanctis, Luisa, De Vita, Emanuele, Del Ben, Maria, Di Costanzo, Alessia, Di Taranto, Maria Donata, Fasano, Tommaso, Gentile, Luigi, Gentile, Marco, Ghirardello, Omar, Grigore, Liliana, Lussu, Milena, Meregalli, Giancarla, Moffa, Simona, Montalcini, Tiziana, Morgia, Valeria, Nascimbeni, Fabio, Pasta, Andrea, Pavanello, Chiara, Saitta, Antonino, Scicali, Roberto, Siepi, Donatella, Spagnolli, Walter, Spina, Rossella, Sticchi, Elena

مصطلحات موضوعية: Dutch Lipid Clinic Network score, Familial hypercholesterolemia, Genetic testing, Cardiology and Cardiovascular Medicine

الوصف: Background and aims: Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification. Methods: This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving the identification of patients with genetic dyslipidaemias, including FH. Results: The DLCN score was applied on a sample of 1377 adults (mean age 42.9 ± 14.2 years) with genetic diagnosis of FH, resulting in 28.5% of the sample classified as probable FH and 37.9% as classified definite FH. Among these subjects, 43.4% had at least one missing data out of 8, and about 10.0% had 4 missing data or more. When analyzed based on the type of missing data, a higher percentage of subjects with at least 1 missing data in the clinical history or physical examination was classified as possible FH (DLCN score 3–5). We also found that using real or estimated pre-treatment LDL-C levels may significantly modify the DLCN score. Conclusions: Although the DLCN score is a useful tool for physicians in the diagnosis of FH, it may be limited by the complexity to retrieve all the essential information, suggesting a crucial role of the clinical judgement in the identification of FH subjects.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30270079; info:eu-repo/semantics/altIdentifier/wos/WOS:000445908000062; volume:277; firstpage:413; lastpage:418; numberofpages:6; journal:ATHEROSCLEROSIS; info:eu-repo/grantAgreement/EC/H2020/PHC-03-2015/667837-2; http://hdl.handle.net/11585/653011Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85053847614; www.elsevier.com/locate/atherosclerosis

الإتاحة: https://doi.org/10.1016/j.atherosclerosis.2018.08.013Test
http://hdl.handle.net/11585/653011Test

المؤلفون: Sancho, Veronica, Daniele, Giuseppe, Lucchesi, Daniela, Lupi, Roberto, Ciccarone, Annamaria, Penno, Giuseppe, Bianchi, Cristina, Dardano, Angela, Miccoli, Roberto, Del Prato, Stefano

المساهمون: Sancho, Veronica, Daniele, Giuseppe, Lucchesi, Daniela, Lupi, Roberto, Ciccarone, Annamaria, Penno, Giuseppe, Bianchi, Cristina, Dardano, Angela, Miccoli, Roberto, Del Prato, Stefano

مصطلحات موضوعية: Biochemistry, Genetics and Molecular Biology (all), Agricultural and Biological Sciences (all)

الوصف: Background and aims: An intra-islet incretin system has been recently suggested to operate through modulation of the expression and activity of proconvertase 1/3 and 2 (PC1/3, PC2) in pancreatic alpha-cell accounting for local release of GLP-1. Little is known, whether this alpha-cell activity can be affected by the metabolic alterations occurring in type 2 diabetes, such as hyperglycemia, hyperlipidemia or hyperglucagonemia. Materials and methods: AlphaTC1/6 cells from a mice pancreatic cell line were incubated in the presence of two glucose (G) concentration (5.5 and 16.7 mM) for 16 h with or without free fatty acid, IL6 or glucagon. GLP-1 secretion was measured by ELISA and expression of PC1/3 and PC2 by RT-PCR and western blot; cell viability was determined by MTT method, Reactive Oxygen Species generation (ROS) by H2DCFDA fluorescence and apoptosis by Annexin staining and Propidium Iodine (PI) fluorescence. Results: Upon 16.7G incubation, GLP-1 secretion (total and active) was significantly increased in parallel with a significant increment in PC1/3 expression, a slight increase in cell viability and ROS generation and by a decrement in PC2 expression with no change in cell apoptosis. When cells were incubated at 5.5mM glucose with FFA, also an increment in GLP-1 secretion and PC1/3 expression was observed together an increment in ROS generation, a decrement in cell viability, and a modest increment in apoptosis. When incubated with 16.7mM glucose with FFA, the increment in GLP-1 secretion was reduced to basal, accompanied by an increment in apoptosis and ROS generation. This was also observed with IL-6, but in this case, no modification in ROS generation or apoptosis was observed when compared to 16.7mM glucose. The presence of glucagon did not modify any of the parameters studied. Conclusion: These data suggest that under hyperglycemic, hyperlipidemia or inflammatory conditions, alpha cells can increase expression PC1/3 and activate GLP-1 secretion, which may contribute protecting both alpha and ...

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29121068; info:eu-repo/semantics/altIdentifier/wos/WOS:000414769900085; volume:12; issue:11; journal:PLOS ONE; http://hdl.handle.net/11568/881432Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85033772515; http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0187836&type=printableTest

الإتاحة: https://doi.org/10.1371/journal.pone.0187836Test
http://hdl.handle.net/11568/881432Test
http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0187836&type=printableTest

المؤلفون: DAURIZ, Marco, Bonadonna, Riccardo, TROMBETTA, Maddalena, BOSELLI, Maria Linda, Santi, Lorenza, BRANGANI, Corinna, PICHIRI, Isabella, Bianchi, Cristina, Miccoli, Roberto, Del Prato, Stefano, BONORA, Enzo

المساهمون: Dauriz, Marco, Bonadonna, Riccardo, Trombetta, Maddalena, Boselli, Maria Linda, Santi, Lorenza, Brangani, Corinna, Pichiri, Isabella, Bianchi, Cristina, Miccoli, Roberto, Del Prato, Stefano, Bonora, Enzo

مصطلحات موضوعية: Newly-diagnosed Type 2 Diabetes, insulin resistance, beta-cell function, oral glucose tolerance test, insulin clamp

الوصف: Presence and frequency of beta cell (BC) dysfunction (BCD) and insulinresistance (IR) in patients with newly diagnosed type 2 diabetes mellitus(NDT2D) are imperfectly known, because previous studies used small cohortsand/or only surrogate indexes of BC function and IR. We assessedBC function and IR with state-of-art methods in the VNDS. In 712 GADAnegative,drug naïve, consecutive Italian NDT2D patients we assessed: 1.standard parameters; 2. insulin sensitivity (IS) by the euglycaemic insulinclamp); 3. BC function by state-of-art modeling of prolonged (5 hours) OGTTderivedglucose/C-peptide curves. Thresholds for BCD and IR were the25th percentiles of BC function and IS assessed with the same methodsof the VNDS in Italian subjects with normal glucose regulation of the GENFIEV(n=340) and GISIR (n=386) studies, respectively. In the VNDS, 89.8%[95% C.I.: 87.6 - 92.0%] and 87.8% [85.4 - 90.2] patients had BCD and IR,respectively. Patients with only one defect were 19.7% [16.8 - 22.6]. IsolatedBCD and isolated IR were present in 10.9% [8.6 - 13.2] and 8.9% [6.8 - 11.0]patients, respectively. Coexistence of BCD and IR was observed in 78.9%[75.9 - 81.9] of the patients. 1.4% [0.5 - 2.3] of the patients had no detectablealterations in BC function and IS. Patients (19.7%) with only one metabolicdefect had lower BMI, fasting glucose, HbA1c, triglycerides and BC function,and higher HDL-cholesterol and IS than patients with both BCD and IR(p<0.01 or less after Bonferroni’s correction). In conclusion, in NDT2DM patients:1. at least 75.9% have both BCD and IR; 2. At least 87.6% and 85.4%have BCD and IR, respectively; 3. At least 16.8% have only one defect anda signifi cantly different (milder) metabolic phenotype compared to patientswith both defects. These fi ndings may be relevant to therapeutic strategiescentered on the metabolic phenotype of the patient. ClinicalTrial.gov Identifiers: NCT00879801, NCT01526720.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000359482702090; ispartofbook:Diabetes; American Diabetes Association 75th Scientific Meeting; volume:64; issue:Supplement 1; firstpage:A407; lastpage:A407; numberofpages:1; journal:DIABETES; http://hdl.handle.net/11562/929136Test; http://diabetes.diabetesjournals.org/content/64/Supplement_1/A382.full.pdf+htmlTest

الإتاحة: https://doi.org/10.2337/db15-1472-1800Test
http://hdl.handle.net/11562/929136Test
http://diabetes.diabetesjournals.org/content/64/Supplement_1/A382.full.pdf+htmlTest

المؤلفون: Lucchesi, Daniela, Popa, Simona Georgiana, Sancho, Veronica, Giusti, Laura, Garofolo, Monia, Daniele, Giuseppe, Pucci, Laura, Miccoli, Roberto, Penno, Giuseppe, Del Prato, Stefano

المساهمون: Regione Toscana, Italy

المصدر: Cardiovascular Diabetology ; volume 17, issue 1 ; ISSN 1475-2840

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

الإتاحة: https://doi.org/10.1186/s12933-018-0720-1Test